Health-Status Outcomes in Older Patients With Myocardial Infarction: Physiology-Guided Complete Revascularization Versus Culprit-Only Strategy.

anxiety frailty myocardial infarction physical functional performance quality of life

Journal

Circulation. Cardiovascular quality and outcomes
ISSN: 1941-7705
Titre abrégé: Circ Cardiovasc Qual Outcomes
Pays: United States
ID NLM: 101489148

Informations de publication

Date de publication:
18 Jun 2024
Historique:
medline: 18 6 2024
pubmed: 18 6 2024
entrez: 18 6 2024
Statut: aheadofprint

Résumé

The FIRE trial (Functional Assessment in Elderly Myocardial Infarction Patients With Multivessel Disease) enrolled 1445 older (aged ≥75 years) patients with myocardial infarction and multivessel disease in Italy, Spain, and Poland. Patients were randomized to physiology-guided complete revascularization or treatment of the only culprit lesion. Physiology-guided complete revascularization significantly reduced ischemic adverse events at 1 year. This prespecified analysis investigated the changes between the 2 study groups in angina status, quality of life, physical performance, and frailty. Patients underwent validated scales at hospital discharge (baseline) and 1 year later. Angina status was evaluated using the Seattle Angina Questionnaire, health-related quality of life by EQ visual analog scale, physical performance by short physical performance battery, and frailty by the clinical frailty scale. Mixed models for repeated measures analysis were used to study the association between the treatment arms, time, and scales. Baseline and 1-year Seattle Angina Questionnaire, EQ visual analog scale, short physical performance battery, and clinical frailty scale were collected in around two-thirds of the entire FIRE study population. The mean age was 80.9±4.6 years (female sex, 35.9%). Overall, 35.3% were admitted for ST-segment-elevation myocardial infarction, whereas the others were admitted for non-ST-segment-elevation myocardial infarction. Physiology-guided complete revascularization, compared with culprit-only revascularization, was associated with greater improvement in terms of angina status (Seattle Angina Questionnaire summary score, 7.3 [95% CI, 6.1-8.6] points), health-related quality of life (EQ visual analog scale, 6.2 [95% CI, 4.4-8.1] points), and physical performance (short physical performance battery, 1.1 [95% CI, 0.9-1.3] points). After 1 year, patients randomized to culprit-only revascularization experienced a deterioration in frailty status (clinical frailty scale, 0.2 [95% CI, 0.1-0.3] points), which was not observed in patients randomized to physiology-guided complete revascularization. The present analysis suggested that a physiology-guided complete revascularization is associated with consistent benefits in terms of angina status, quality of life, physical performance, and the absence of further deterioration of the frailty status. URL: https://www.clinicaltrials.gov; Unique identifier: NCT03772743.

Sections du résumé

BACKGROUND UNASSIGNED
The FIRE trial (Functional Assessment in Elderly Myocardial Infarction Patients With Multivessel Disease) enrolled 1445 older (aged ≥75 years) patients with myocardial infarction and multivessel disease in Italy, Spain, and Poland. Patients were randomized to physiology-guided complete revascularization or treatment of the only culprit lesion. Physiology-guided complete revascularization significantly reduced ischemic adverse events at 1 year. This prespecified analysis investigated the changes between the 2 study groups in angina status, quality of life, physical performance, and frailty.
METHODS UNASSIGNED
Patients underwent validated scales at hospital discharge (baseline) and 1 year later. Angina status was evaluated using the Seattle Angina Questionnaire, health-related quality of life by EQ visual analog scale, physical performance by short physical performance battery, and frailty by the clinical frailty scale. Mixed models for repeated measures analysis were used to study the association between the treatment arms, time, and scales.
RESULTS UNASSIGNED
Baseline and 1-year Seattle Angina Questionnaire, EQ visual analog scale, short physical performance battery, and clinical frailty scale were collected in around two-thirds of the entire FIRE study population. The mean age was 80.9±4.6 years (female sex, 35.9%). Overall, 35.3% were admitted for ST-segment-elevation myocardial infarction, whereas the others were admitted for non-ST-segment-elevation myocardial infarction. Physiology-guided complete revascularization, compared with culprit-only revascularization, was associated with greater improvement in terms of angina status (Seattle Angina Questionnaire summary score, 7.3 [95% CI, 6.1-8.6] points), health-related quality of life (EQ visual analog scale, 6.2 [95% CI, 4.4-8.1] points), and physical performance (short physical performance battery, 1.1 [95% CI, 0.9-1.3] points). After 1 year, patients randomized to culprit-only revascularization experienced a deterioration in frailty status (clinical frailty scale, 0.2 [95% CI, 0.1-0.3] points), which was not observed in patients randomized to physiology-guided complete revascularization.
CONCLUSIONS UNASSIGNED
The present analysis suggested that a physiology-guided complete revascularization is associated with consistent benefits in terms of angina status, quality of life, physical performance, and the absence of further deterioration of the frailty status.
REGISTRATION UNASSIGNED
URL: https://www.clinicaltrials.gov; Unique identifier: NCT03772743.

Identifiants

pubmed: 38887951
doi: 10.1161/CIRCOUTCOMES.123.010490
doi:

Banques de données

ClinicalTrials.gov
['NCT03772743']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e010490

Auteurs

Gianluca Campo (G)

Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Italy (G. Campo, S.B.).

Vincenzo Guiducci (V)

Cardiology Unit, Azienda Unità Sanitaria Locale - Istituto di Ricovero e Cura a Carattere Scientifico Reggio Emilia, S. Maria Nuova Hospital, Italy (V.G., S.M.d.).

Javier Escaned (J)

Hospital Clínico San Carlos Istituto de Investigacion Sanitaria Hospital San Carlos, Complutense University of Madrid, Spain (J.E.).

Raul Moreno (R)

Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares, Madrid, Spain (R.M.).
Instituto de Investigación Hospital La Paz, University Hospital La Paz, Madrid, Spain (R.M.).

Gianni Casella (G)

Cardiology Unit, Ospedale Maggiore, Bologna, Italy (G. Casella, A.C.).

Caterina Cavazza (C)

Cardiovascular Department, Infermi Hospital, Rimini, Italy (C.C.).

Enrico Cerrato (E)

Interventional Cardiology Unit, San Luigi Gonzaga University Hospital, Orbassano, and Rivoli Infermi Hospital ASLTO3, Turin, Italy (E.C.).

Marco Contarini (M)

Cardiology Unit, Umberto I Hospital, Azienda Sanitaria Provinciale Siracusa, Italy (M.C.).

Marco Arena (M)

S.C. Cardiologia, Ospedale Sant'Andrea, La Spezia, Italy (M.A.).

Andres Iniguez Romo (A)

Hospital Alvaro Conqueiro de Vigo, Spain (A.I.R.).

Enrique Gutiérrez Ibañes (E)

Hospital General Universitario Gregorio Maranon, Madrid, Spain (E.G.I.).

Roberto Scarsini (R)

Azienda Ospedaliero Universitaria Integrata di Verona, Italy (R.S.).

Giuseppe Vadalà (G)

Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone, Italy (G.V.).

Giuseppe Andò (G)

Azienda Ospedaliero Universitaria Policlinico Gaetano Martino, Messina, Italy (G.A.).

Gerlando Pilato (G)

Hospital San Giovanni di Dio, Azienda Sanitaria Provinciale Agrigento, Italy (G.P.).

Sergio Musto d'Amore (S)

Cardiology Unit, Azienda Unità Sanitaria Locale - Istituto di Ricovero e Cura a Carattere Scientifico Reggio Emilia, S. Maria Nuova Hospital, Italy (V.G., S.M.d.).

Alessandro Capecchi (A)

Cardiology Unit, Ospedale Maggiore, Bologna, Italy (G. Casella, A.C.).

Ramiro Trillo Nouche (R)

Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain (R.T.N.).

Elisabetta Moscarella (E)

Azienda Ospedaliero Sant'Anna e San Sebastiano, Caserta, Italy (E.M.).

Alfonso Gambino (A)

Ospedale Santa Croce, Moncalieri, Italy (A.G.).

Marco Pavani (M)

Ospedale Santissima Annunziata, Savigliano, Italy (M.P.).

Anna Zanetti (A)

We4 Clinical Research, Milan, Italy (A.Z., N.P.).

Nicola Pesenti (N)

We4 Clinical Research, Milan, Italy (A.Z., N.P.).

Dariusz Dudek (D)

Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland (D.D.).

Emanuele Barbato (E)

Department of Clinical and Molecular Medicine, Sapienza University of Rome, Italy (E.B.).

Matteo Tebaldi (M)

Cardiology Unit, Ospedale "Degli Infermi" di Faenza, Italy (M.T.).

Simone Biscaglia (S)

Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Italy (G. Campo, S.B.).

Classifications MeSH